{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:16:09Z","timestamp":1790788569845,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ijantimicag.2010.08.017","type":"journal-article","created":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T09:35:38Z","timestamp":1292405738000},"page":"78-81","source":"Crossref","is-referenced-by-count":5,"title":["Does aminoglycoside therapy cause significant acute kidney injury in febrile neutropenia?"],"prefix":"10.1016","volume":"37","author":[{"given":"Krispin M.","family":"Hajkowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2010.08.017_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003038","article-title":"\u03b2-Lactam versus \u03b2-lactam\u2013aminoglycoside combination therapy in cancer patients with neutropenia","author":"Paul","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2010.08.017_bib0010","first-page":"229b","article-title":"Piperacillin\/tazobactam vs. piperacillin\/tazobactam plus amikacin as empiric therapy for fever in neutropenic patients","volume":"90","author":"Esteve","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ijantimicag.2010.08.017_bib0015","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2010.08.017_bib0020","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3201\/eid0702.010206","article-title":"Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics","volume":"7","author":"Weinstein","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"2 Suppl. 1","key":"10.1016\/j.ijantimicag.2010.08.017_bib0025","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijantimicag.2010.08.017_bib0030","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.40.5.1108","article-title":"Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto Infection Program","volume":"40","author":"Cometta","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2010.08.017_bib0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2141.1990.tb07937.x","article-title":"Ceftazidime plus teicoplanin versus ceftazidime plus amikacin as empiric therapy for fever in cancer patients with granulocytopenia","volume":"76","author":"Meunier","year":"1990","journal-title":"Br J Haematol"},{"issue":"15 Suppl","key":"10.1016\/j.ijantimicag.2010.08.017_bib0040","article-title":"Outpatient single dose ceftriaxone and amikacin vs. imipenem\/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever and neutropenia. A randomized, prospective clinical trial","volume":"22","author":"Ahmed-El Borollosy","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijantimicag.2010.08.017_bib0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000048547","article-title":"Comparison of cefepime versus ceftriaxone\u2013amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients","volume":"47","author":"Borbolla","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2010.08.017_bib0050","first-page":"89","article-title":"A comparison of imipenem monotherapy versus cefoperazone\/sulbactam plus amikacin combination treatment in febrile neutropenic cancer patients","volume":"11","author":"Dincol","year":"1998","journal-title":"Cancer J"},{"key":"10.1016\/j.ijantimicag.2010.08.017_bib0055","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s005200050184","article-title":"Monotherapy with piperacillin\/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients","volume":"6","author":"Hess","year":"1998","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijantimicag.2010.08.017_bib0060","doi-asserted-by":"crossref","first-page":"717","DOI":"10.7326\/0003-4819-124-8-199604150-00003","article-title":"Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis","volume":"124","author":"Hatala","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2010.08.017_bib0065","article-title":"Rapid response: risk of aminoglycoside nephrotoxicity in neutropenic fever may be overestimated","author":"Cooke","year":"2003","journal-title":"BMJ"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910004061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910004061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T02:53:26Z","timestamp":1559876006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857910004061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0924857910004061"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.08.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}